Clinical Trials Directory

We are doing this to see the effects of giving long-term red blood cell exchange transfusion to patients with sickle cell disease (SCD). We want to know if exchange blood transfusion may help with serious complications of SCD or reduce the chances of a new, serious problem happening.

We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.

We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.

The purpose of this research study is to determine whether data from mobile health technologies (such as smartwatches and smartphones) can be used to assess risk of prediabetes and type 2 diabetes. Using data from smartphones and smartwatches, we may be able to develop a noninvasive procedure for identifying patients who are at risk and should be tested for diabetes. Participants can earn up to $50. For more information about who can be in this study, please contact the study team at diabeteswatch2@duke.edu.

If you join this study, you will first go through a screening period to make sure you qualify. If you qualify, you will be placed into one of two groups by chance, like drawing names from a hat. Group 1 will get one dose of a medicine called rademikibart. Group 2 will get one dose of a placebo, which looks like the medicine but does not have any active drug. The study will include about nine visits over a period of eight to thirty‑four weeks.

We are doing this study to get more information about the safety and performance of the Signia® circular adapter and stapler (the study technology). This device is FDA-approved for use as a tool to connect or re-connect tissues after a surgery. We want to know how successful it is at promoting healing for people who have left sided colon, sigmoid, or rectal resections at Duke.

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.

We are doing this study to find out if a study drug called ivosidenib is a safe and effective option for locally advanced or metastatic conventional chondrosarcoma with an isocitrate dehydrogenase 1 (IDH1) mutation.